Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma.

Mepolizumab vs placebo was associated with a numerical trend for improved pre‐bronchodilator FEV 1 from baseline in all patients except those with fungal sensitization only, although this may be due to the small sample size (n = 51) for this group (Figure 1C ; Table S4 ).

also in 1,012 other papers

SGRQ and ACQ‐5 scores also showed a trend for improvement with mepolizumab vs placebo in all groups (Figure S1 ; Table S4 ); the improvement from baseline with mepolizumab exceeded the minimum clinically important difference (MCID) of 4‐points for SGRQ total score and 0.5‐points for ACQ‐5 score in all groups (Table S4 ). 8 , 9 In addition, mepolizumab vs placebo reduced blood eosinophil counts from baseline by 80%‐87% and reduced eosinophil cationic protein and eosinophil‐derived neurotoxin levels in all groups (Table S6 ).

also in 53,322 other papers